Patient Characteristics (n = 67)
| Characteristic | Mean ± SD |
| Age (y) | |
| Mean | 72 (SD, 7) |
| Median | 72 |
| Interquartile range | 67–76 |
| PSA PET (ng/mL) | |
| Mean | 289.0 (SD, 638.1) |
| Median | 53.2 |
| Interquartile range | 5.8–334.6 |
| Difference between date of PET and date of CI (mo) | |
| Mean | 1.0 (SD, 1.5) |
| Median | 1.0 |
| Interquartile range | 0–2.0 |
| ≥T3a (n) | 34/49 (69%) |
| N1 (n) | 20/42 (48%) |
| ISUP grade group ≥ 4 (n) | 35/54 (65%) |
| High-risk (D’Amico stratification) (n) | 52/60 (87%) |
| Previous therapies (n) | |
| Prostatectomy (n) | 43/67 (64%) |
| External-beam radiation therapy (n) | 7/67 (10%) |
| Salvage radiation therapy (n) | 29/67 (43%) |
| Hormonal therapy (n) | 67/67 (100%) |
| Docetaxel (n) | 25/67 (37%) |
| Cabazitaxel (n) | 4/67 (6%) |
| Abiraterone/enzalutamide/apalutamide (n) | 25/67 (37%) |
| 223Ra (n) | 11/67 (16%) |
| Palliative radiation therapy (n) | 12/67 (18%) |
| Hormonal therapy at time of scan (n) | 36/67 (54%) |
| PET/MRI (n) | 15/67 (22%) |
| PET/CT (n) | 52/67 (78%) |
ISUP = International Society of Urologic Pathologists.